Cancer research. Over thirteen years in pharmaceutical consulting. Now an advisory practice helping healthcare organisations adopt AI with the same rigour the industry already demands.
My career began in cancer research at the Institute of Cancer Research, where I co-authored published work on cellular signalling. That foundation in scientific rigour has shaped every chapter since.
For over thirteen years I worked in pharmaceutical consulting — HEOR, pricing, market access, and value communication. I've led HTA submissions across thirteen European countries, run payer research programmes, and trained teams in negotiation across rare disease, oncology, haematology and diabetes.
In 2025 I turned toward a question I couldn't ignore: how does a regulated industry adopt AI responsibly? I enrolled in an MA at the University of Southampton, joined the BCS, and began advising organisations on exactly that — alongside building a reference guide, a weekly brief, and a literacy series in the open.
Because the stakes are different in pharma. A model that hallucinates a citation in a consumer chatbot is an annoyance; the same error in an HTA submission is a patient-safety event. I care about work that's intellectually honest — and I don't believe that's at odds with genuine curiosity about what AI can do.
